Compare Natera Inc. Common Stock (NTRA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Shell PLC — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Shell PLC trades at $104.44 (market cap $294.95B). The key difference: Shell PLC is far larger — about 5.2× Natera Inc. Common Stock's market cap, and Shell PLC pays a 3.02% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Shell PLC for 91 Days on average.
| NTRA | SHEL | |
|---|---|---|
Market Cap | $57.03B | $294.95B |
Volume | 1,131,157 | 6,021,309 |
Sector | Health | Energy |
52-Week High | $425.64 | $103.58 |
52-Week Low | $179.42 | $70.31 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $56.18B | $336.65B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Shell (SHEL) trades at $102.99, up 1.38% on the day, near its 52-week high. The stock shows strong technical momentum with bullish moving averages, though oscillators indicate overbought conditions. Fundamentally, the company delivered earnings beats in Q1 and Q2 2026, with a forward P/E of 11.39 suggesting reasonable valuation. Recent news highlights strategic LNG expansion, including the Phase 2 approval for LNG Canada, positioning Shell for long-term growth in global gas markets.
The outlook for Shell remains positive, supported by robust cash flows, strategic investments in LNG, and a favorable analyst consensus with 62% buy ratings. Key risks include exposure to volatile oil prices and execution challenges in major projects. The stock offers value through dividends and growth potential, but investors should monitor energy market dynamics and project timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
